A major trial of a promising gene therapy for Duchenne muscular dystrophy has fallen short, but researchers say the lessons learned could pave the way for better, more effective treatments.

Becker muscular dystrophy (BMD) is a type of muscular dystrophy ... Dystrophinopathies (including BMD and DMD) happen due to certain mutations in the genetic code. One gene, for instance, controls ...

A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD ... is caused by mutations in the DMD gene. While it primarily leads to muscle wasting, a ...

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy ... DMD patients with DMD mutations amenable to exon 44 skipping ...

adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the ...

Global Duchenne Muscular Dystrophy Drugs Market value attained USD 3.9 Billion in 2025. The market will achieve USD 6.5 ...

adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the ...

A patient has died following treatment with Elevidys, the Sarepta Therapeutics product that is the only FDA-approved gene therapy for Duchenne muscular ... genetic mutations lead to deficiency ...